TORNA ALL’ELENCO

Retrospective analysis related to molecular diagnostics for the research of WNVRNA in blood components collected at the SIMT of Asti in Blood Transfusion

2020
ASL Asti

Tipo pubblicazione

Conference Abstract

Autori/Collaboratori (7)Vedi tutti...

Garlisi E

Granero V

Baino D


et alii...

Abstract

Background. West Nile Virus (WNV) is a public health problem. It represents a potential risk because, if transmitted through the transfusion, it could cause serious neuroinvasive diseases (WNND) in immunocompromised patients (generally less than 1% of infected people develop WNND). There is no definitive treatment for WNV infection; therefore, protection from mosquito bites and other preventive measures are essential. For this reason, the Italian National Blood Center (CNS) requires the WNV-RNA test mandatory in periods and places of increased circulation and spread of the virus. We evaluated, with a retrospective analysis about 2018 and 2019, the local epidemiological context, performed a plan of risk assessment for the Residual Risk (RR) of the transfusion's transmission of WNV infection and estimated the potential economic impact for the ASL of Asti and the Piedmont Region, if the WNV-RNA test has not been performed. Methods. Total donations in 2018 and 2019: 34.109. Tests performed in the mandatory periods (for 2018 and 2019): 10.783. Molecular diagnostics: Cobas TaqScreen WNV Test, Roche. References used for the RR: 1. Schreiber G et al, 1996; 2. Faddy H et al, 2018 (window phase considered: 3 days) Estimation of cost: according to Paternoster et al (PLoS 2017). Results. There was one case of positivity (in 2018) respect the 10.783 WNV-RNA tests. Expenditure by the ASL to perform the WNV-RNA screening test: € 116.280/year and cover the screening of approximately 5.800 donations each year. Formula 1: RR in the two years = 0,00100% ratio% on 100.000 donations (if they had been screened) = 0,00927% ratio% of 34.109 donations (if they had been screened) = 0,00316% Formula 2: Year 2018: RR = 0,00015% ratio% on 100.000 donations = 0,0028% ratio% of 17.109 donations = 0,00047% Year 2019: RR = not calculable (0 positivity) Years 2018-2019: RR 3.81 ? 10-5% ratio% on 100.000 donations = 0,000353% ratio% on 34.109 (year 2018 and 2019) = 0,000121% ? RR reductio

DOI : 10.2450/2020.S2

Keywords

risk factor; vision; prevalence; monoclonal immunoglobulinemia; male; human; gender; female; follow up; data extraction; data analysis software; controlled study; conference abstract; capillary electrophoresis; blood group ABO system; blood group; blood donor; blood component; aged; adult; monoclonal antibody;